Cited by 657Alzheimer's disease research and treatmentsCholinesterase and Neurodegenerative DiseasesDementia and Cognitive Impairment Research

The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.

NSAIDs and enantiomers of flurbiprofen target γ-secretase and lower Aβ42 in vivo

Open access

Eriksen, Jason L., Sagi, Sarah A., Smith, Tawnya E., Weggen, Sascha, Das, Pritam, McLendon, D.C., Ozols, Victor V., Jessing, Kevin W., Zavitz, Kenton H., Koo, Edward H., Golde, Todd E.·2003·Journal of Clinical Investigation

DOI 10.1172/jci18162PMC PMC166298

Open this paper in CoChat — free account Open PDF

Abstract

Epidemiologic studies demonstrate that long-term use of NSAIDs is associated with a reduced risk for the development of Alzheimer disease (AD). In this study, 20 commonly used NSAIDs, dapsone, and enantiomers of flurbiprofen were analyzed for their ability to lower the level of the 42-amino-acid form of amyloid beta protein (Abeta42) in a human H4 cell line. Thirteen of the NSAIDs and the enantiomers of flurbiprofen were then tested in acute dosing studies in amyloid beta protein precursor (APP) transgenic mice, and plasma and brain levels of Abeta and the drug were evaluated. These studies show that (a). eight FDA-approved NSAIDs lower Abeta42 in vivo, (b). the ability of an NSAID to lower Abeta42 levels in cell culture is highly predicative of its in vivo activity, (c). in vivo Abeta42 lowering in mice occurs at drug levels achievable in humans, and (d). there is a significant correlation between Abeta42 lowering and levels of ibuprofen. Importantly, flurbiprofen and its enantiomers selectively lower Abeta42 levels in broken cell gamma-secretase assays, indicating that these compounds directly target the gamma-secretase complex that generates Abeta from APP. Of the compounds tested, meclofenamic acid, racemic flurbiprofen, and the purified R and S enantiomers of flurbiprofen lowered Abeta42 levels to the greatest extent. Because R-flurbiprofen reduces Abeta42 levels by targeting gamma-secretase and has reduced side effects related to inhibition of cyclooxygenase (COX), it is an excellent candidate for clinical testing as an Abeta42 lowering agent.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1172/jci18162

Cites

52 of 52 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Glutamate neurotoxicity and diseases of the nervous system
Choi, D. W. (1988) · Neuron · doi:10.1016/0896-6273(88)90162-6 · Cited by 8,188
Alzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484
Alzheimer's Disease: Genes, Proteins, and Therapy
Selkoe, D. J. (2001) · Physiological Reviews · doi:10.1152/physrev.2001.81.2.741 · Cited by 6,063
Inflammation and Alzheimer’s disease
Akiyama, H. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00124-x · Cited by 4,514
Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice
Hsiao, K., Chapman, P., Nilsen, S., Eckman, C., Harigaya, Y., Younkin, S., Yang, F., & Cole, G. (1996) · Science · doi:10.1126/science.274.5284.99 · Cited by 4,210
Secreted amyloid β–protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease
Scheuner, D., Eckman, C., Jensen, M., Song, X., Citron, M., Suzuki, N., Bird, T. D., Hardy, J., Hutton, M., Kukull, W., et al. (1996) · Nature Medicine · doi:10.1038/nm0896-864 · Cited by 2,599
Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein
Games, D., Adams, D., Alessandrini, R., Barbour, R., Borthelette, P., Blackwell, C., Carr, T., Clemens, J., Donaldson, T., Gillespie, F., et al. (1995) · Nature · doi:10.1038/373523a0 · Cited by 2,516
Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and γ-secretase activity
Wolfe, M. S., Xia, W., Ostaszewski, B. L., Diehl, T. S., Kimberly, W. T., & Selkoe, D. J. (1999) · Nature · doi:10.1038/19077 · Cited by 1,959
Statins and the risk of dementia
Jick, H., Zornberg, G. L., Jick, S. S., Seshadri, S. S., & Drachman, D. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03155-x · Cited by 1,764
Increased amyloid-β42(43) in brains of mice expressing mutant presenilin 1
Duff, K., Eckman, C., Zehr, C., Yu, X., Prada, C.-M., Pérez‐Tur, J., Hutton, M., Buée, L., Harigaya, Y., Yager, D., et al. (1996) · Nature · doi:10.1038/383710a0 · Cited by 1,486

Flagged first, then by citations

Show all 52 references

Research works printed but not linked: 3

Wechter, 2000, Cancer Res., 60, 2203
Edbauer, 2003, Nat. Cell Biol., 7, 7
Murray, 2000, Clin. Pharmacol. Ther., 67, 103

Sorted by citations

Items 501–600 of 657

Deficiency in either COX-1 or COX-2 genes does not affect amyloid beta protein burden in amyloid precursor protein transgenic mice
Park, S. A., Chevallier, N., Tejwani, K., Hung, M. M., Maruyama, H., Golde, T. E., & Koo, E. H. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.07.015 · Cited by 8
Effect of Tarenflurbil on Cognitive Decline and Activities of Daily Living in Patients With Mild Alzheimer Disease
Green, R. C., Schneider, L. S., Amato, D. A., Beelen, A. P., Wilcock, G. K., Swabb, E. A., & Zavitz, K. H. (2016) · Cited by 8
Consideration of a Pharmacological Combinatorial Approach to Inhibit Chronic Inflammation in Alzheimer’s Disease
McLarnon, J. G. (2019) · Current Alzheimer Research · doi:10.2174/1567205016666191106095038 · Cited by 8
γ-Secretase modulators exhibit selectivity for modulation of APP cleavage but inverse γ-secretase modulators do not
Lessard, C. B., Rodriguez, E., Ladd, T. B., Minter, L. M., Osborne, B. A., Miele, L., Golde, T. E., & Ran, Y. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00622-5 · Cited by 8
Kognitive Störungen: Koma, Delir, Demenz
Förstl, H. (2006) · Springer eBooks · doi:10.1007/3-540-30887-3_5 · Cited by 8
γ-secretase modulators: hopes and setbacks for the future of Alzheimer’s treatment
Evin, G. M. (2008) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.8.11.1611 · Cited by 8
SAR-studies of γ-secretase modulators with PPARγ-agonistic and 5-lipoxygenase-inhibitory activity for Alzheimer’s disease
Flesch, D., Neß, J., Lamers, C., Dehm, F., Popella, S., Steri, R., Ogorek, I., Hieke, M., Dannhardt, G., Werz, O., et al. (2014) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2014.12.073 · Cited by 7
[The effect of ibuprofen and acetylsalicylic acid on cognitive impairment, total antioxidant power and isoprostane serum].
Ibáñez-Hernández, M. G., Macías-Islas, M. Á., Zavalza-Gómez, A. B., Pacheco-Moisés, F. P., & Ortíz, G. G. (2008) · PubMed · Cited by 7
Drug Development for Alzheimer's Disease: Recent Progress
Ji, W., & Ha, I. (2010) · Experimental Neurobiology · doi:10.5607/en.2010.19.3.120 · Cited by 7
Membrane anchoring γ-secretase modulators with terpene-derived moieties
Naumann, E. C., Göring, S., Ogorek, I., Weggen, S., & Schmidt, B. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.04.070 · Cited by 7
Amyloid β Hypothesis in the Development of Therapeutic Agents for Alzheimer’s Disease
Adeniji, A. O., Adams, P. W., & Mody, V. V. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802810-0.00007-6 · Cited by 7
An NSAID-like Compound, FT-9, Preferentially Inhibits γ-Secretase Cleavage of the Amyloid Precursor Protein Compared to Its Effect on Amyloid Precursor-like Protein 1
Frigerio, C. S., Kukar, T. L., Fauq, A. H., Engel, P. C., Golde, T. E., & Walsh, D. M. (2009) · Biochemistry · doi:10.1021/bi901237k · Cited by 7
Relevant Practical Applications of Bioreduction Processes in the Synthesis of Active Pharmaceutical Ingredients
Tasnádi, G., & Hall, M. (2013) · Wiley eBooks · doi:10.1002/9783527665785.ch13 · Cited by 7
β‐Amyloid Therapeutic Strategies for Alzheimer's Disease
Imbimbo, B. P., & Speroni, F. (2005) · Wiley eBooks · doi:10.1002/0471266949.bmc112 · Cited by 6
Targeting the blood-brain barrier with lipoprotein-mimicking nanoparticles loaded with flurbiprofenaxetil and coated with apolipoprotein E3
Laabs, M., Mulac, D., & Langer, K. (2025) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2025.107272 · Cited by 8
The role of APOE ε4 in modulating the relationship between non-genetic risk factors and dementia: a system review and meta-analysis
Huang, X., Huang, L., Tan, C., Wei, J.-M., Zhang, X.-H., Tan, L., & Xu, W. (2025) · Journal of Neurology · doi:10.1007/s00415-025-13434-0 · Cited by 6
Identification of four ene reductases and their preliminary exploration in the asymmetric synthesis of (R)-dihydrocarvone and (R)-profen derivatives
Shi, Q., Jia, Y., Wang, H., Li, S., Li, H., Guo, J., Dou, T., Qin, B. Y., & You, S. (2021) · Enzyme and Microbial Technology · doi:10.1016/j.enzmictec.2021.109880 · Cited by 6
R-Flurbiprofen Traps Prostaglandins within Cells by Inhibition of Multidrug Resistance-Associated Protein-4
Wobst, I., Ebert, L., Birod, K., Wegner, M.-S., Hoffmann, M., Thomas, D., Angioni, C., Parnham, M. J., Steinhilber, D., Tegeder, I., et al. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms18010068 · Cited by 6
Links Between Amyloid and Tau Biology in Alzheimer’s Disease and Their Cholinergic Aspects
Siegel, G. J., Chauhan, N. B., & Karczma, A. G. (2007) · Springer eBooks · doi:10.1007/978-0-387-46526-5_10 · Cited by 6
Clinical Trials for Disease‐Modifying Drugs Such as BACE Inhibitors
Hsu, H. H. (2010) · Wiley eBooks · doi:10.1002/9780470594087.ch9 · Cited by 6
ROCKs as a potential drug target to combat Alzheimer's disease
Ahmad, F., Rankawat, S., & Pathak, U. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-91287-7.00012-0 · Cited by 5
Znaczenie cyklooksygenaz w neurotoksyczności peptydów amyloidu β w chorobie Alzheimera
Cąkała, M., & Strosznajder, J. B. (2010) · Neurologia i Neurochirurgia Polska · doi:10.1016/s0028-3843(14)60407-2 · Cited by 5
Auraptene Increases the Production of Amyloid-β via c-Jun N-Terminal Kinase-Dependent Activation of γ-Secretase
Jung, C., Uhm, K., Horike, H., Kim, M., Misumi, S., Ishida, A., Ueda, Y., Choi, E., Kim, Y., Michikawa, M., et al. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-141692 · Cited by 5
Rheumatoid arthritis-associated polymorphisms are not protective against Alzheimer's disease
Simmons, C. R., Zou, F., Younkin, S. G., & Estus, S. (2011) · Molecular Neurodegeneration · doi:10.1186/1750-1326-6-33 · Cited by 5
Microwave-assisted synthesis and in vitro stability of N-benzylamide non-steroidal anti-inflammatory drug conjugates for CNS delivery
Eden, B. D., Rice, A. J., Lovett, T. D., Toner, O. M., Geissler, E. P., Bowman, W. E., & Young, S. C. (2019) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2019.04.016 · Cited by 5
Chapter 14 – Oxidative Stress and Neuroinflammation in Alzheimer's Disease and Amyotrophic Lateral Sclerosis: From Biology to Therapeutic Strategies
Mhatre, M., & Hensley, K. (2007) · Elsevier eBooks · doi:10.1016/b978-044452809-4/50155-1 · Cited by 4
β-Amyloid(1–42) induces a reduction in the parallel fiber responses of Purkinje cells: Possible involvement of pro-inflammatory processes
Arbez, N., Gautheron, V., Brugg, B., Mariani, J., & Rovira, C. (2007) · Experimental Gerontology · doi:10.1016/j.exger.2007.05.007 · Cited by 5
Current Strategies of Therapy in Alzheimer`s Disease
Martocchia, A., & Falaschi, P. (2008) · The Open Neuropsychopharmacology Journal · doi:10.2174/1876523800801010019 · Cited by 5
Discovery of a novel regulator, 3β-sulfate-5-cholestenoic acid, of lipid metabolism and inflammation
Wang, Y., Sanyal, A. J., Hylemon, P. B., & Ren, S. (2025) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00426.2024 · Cited by 4
The manipulator behind “Scissors”: γ -secretase and its modulators in Alzheimer’s disease
Ning, G., Fan, X., Du, J., wenxue, Z., Sijia, W., Meinei, C., Xiaolong, D., & Yiming, Q. (2025) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2025.1637671 · Cited by 5
Mild cognitive impairment
Bullock, R. A. (2008) · Psychiatry · doi:10.1016/j.mppsy.2007.11.001 · Cited by 4
Towards Small Molecules as Therapies for Alzheimer’s Disease and Other Neurodegenerative Disorders
Aziz, O., Bürli, R. W., Fischer, D. F., Frearson, J. A., & Wall, M. D. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-803959-5.50004-0 · Cited by 5
Prospects and Challenges for Alzheimer Therapeutics
Wolfe, M. S. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802173-6.00023-x · Cited by 5
Synthesis, Reactions, Characterization and Biological Evaluation of 2,3′‐Bipyridine Derivatives (III)
Attaby, F. A., Abdel‐Fattah, A. M., Shaif, L. M., & Elsayed, M. M. (2013) · Journal of Heterocyclic Chemistry · doi:10.1002/jhet.1521 · Cited by 4
Can rofecoxib delay a diagnosis of Alzheimer's disease in patients with mild cognitive impairment?
Aisen, P. S. S. (2005) · Nature Clinical Practice Neurology · doi:10.1038/ncpneuro0039 · Cited by 4
On the horizon: pathways for drug development in Alzheimer's disease
Hake, A. M., & Farlow, M. R. (2004) · Clinics in Geriatric Medicine · doi:10.1016/s0749-0690(03)00073-9 · Cited by 4
Designing Novel Peptidic Inhibitors of Beta Amyloid Oligomerization
Roy, S. S. (2010) · Libraries and Cultural Resources (University of Calgary) · doi:10.5072/prism/17548 · Cited by 4
Current and emerging therapeutic approaches in Alzheimer’s disease
Chauhan, A., Devi, R., Singh, S., Thakur, R., Bhutani, K., Sharma, R., Kumari, A., Kumar, H., Pal, S., & Saini, A. K. (2026) · Discover Neuroscience · doi:10.1186/s13064-026-00290-5 · Cited by 3
Discovery of novel coumarin triazolyl and phenoxyphenyl triazolyl derivatives targeting amyloid beta aggregation-mediated oxidative stress and neuroinflammation for enhanced neuroprotection
Visansirikul, S., Yanaso, S., Boondam, Y., Prasittisa, K., Prutthiwanasan, B., Chongruchiroj, S., & Sripha, K. (2024) · RSC Medicinal Chemistry · doi:10.1039/d4md00270a · Cited by 4
Effects of flurbiprofen on the functional regulation of serotonin transporter and its misfolded mutant
Hirakawa, H., Taguchi, K., Murakawa, S., Asano, M., Noguchi, S., Kikkawa, S., Harada, K., Adachi, N., Ueyama, T., Hide, I., et al. (2021) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2021.11.006 · Cited by 3
β- and γ-secretases as therapeutic targets for Alzheimer's disease
Swarup, G., Kanik, P., Shekhar, V., & Gupta, S. K. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-23841-3.00011-x · Cited by 4
Dementia treatment
Boeve, B. F., & Boxer, A. L. (2009) · Cambridge University Press eBooks · doi:10.1017/cbo9780511581410.016 · Cited by 3
Amyloid imagingin vivo: implications for Alzheimer's disease management
Verhoeff, N. P. L. G. (2007) · Expert Opinion on Medical Diagnostics · doi:10.1517/17530059.1.3.337 · Cited by 3
Targeting γ-Secretase for the Treatment of Alzheimer’s Disease
Hall, A., & Velter, A. I. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.13789-8 · Cited by 3
How does “Protein Corona” Affect the In vivo Efficiency of Polymeric Nanoparticles? State of Art
(2017) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9781681084930117020011 · Cited by 4
Nonsteroidal Anti-inflammatory Drugs (NSAIDs) and Derived Aβ42-Lowering Molecules for Treatment and Prevention of Alzheimer's Disease (AD)
Weggen, S., Czirr, E., Leuchtenberger, S., & Eriksen, J. L. (2007) · Springer eBooks · doi:10.1007/978-0-387-71522-3_11 · Cited by 3
[Surgical treatment of vesico-ureteral reflux using the Gil Vernet technic. Apropos of 30 cases in children].
Ravasse, P., Shehadi, T., Sijelmassi, R., Gandon, S., & Delmas, P. (1989) · PubMed · Cited by 3
Amyloid β and Alzheimer disease therapeutics: the devil may be in the details
Cirrito, J. R., & Holtzman, D. M. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200319420 · Cited by 3
γ-secretase targeting in Alzheimer's disease
Du, L., Li, G., Wei, Y., & Han, G. (2025) · Journal of Alzheimer s Disease Reports · doi:10.1177/25424823251349529 · Cited by 3
Arachidonic Acid Metabolites: Function in Neurotoxicity and Inflammation in the Central Nervous System
Andreasson, K. I., & Montine, T. J. (2007) · Springer eBooks · doi:10.1007/978-0-387-73894-9_6 · Cited by 3
Understanding and Treating Alzheimer’s Disease
Kumar, U., Roland, A., & Burbidge, S. A. (2007) · Springer eBooks · doi:10.1007/1-4020-5058-5_4 · Cited by 2
E Prostanoid Receptors in Brain Physiology and Disease
Keene, C. D., Cimino, P. J., BREYER, R. M., Montine, K. S., & Montine, T. J. (2008) · Springer eBooks · doi:10.1007/978-0-387-30382-6_15 · Cited by 2
γ-secretase inhibitors for treating Alzheimer’s disease: rationale and clinical data
Panza, F., Frisardi, V., Imbimbo, B. P., Seripa, D., Solfrizzi, V., & Pilotto, A. (2011) · Clinical Investigation · doi:10.4155/cli.11.86 · Cited by 2
Drug Therapy of Alzheimer’s Disease: Cholinesterase Inhibitors, NMDA Antagonists
Nafees, S., Akram, M. F., & Khan, M. A. (2021) · Springer eBooks · doi:10.1007/978-981-16-4558-7_6 · Cited by 2
Aspartic Proteases of Alzheimer’s Disease: β- and γ-Secretases
Wolfe, M. S. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-394447-4.10077-x · Cited by 2
Secretase Processing of Amyloid Precursor Protein (APP) and Neurodegeneration
Marks, N., & Berg, M. J. (2007) · Springer eBooks · doi:10.1007/978-0-387-30379-6_16 · Cited by 2
Ibuprofen in Prevention of Neurodegenerative Diseases
Rainsford, K. D. (2015) · Wiley eBooks · doi:10.1002/9781118743614.ch14 · Cited by 2
Perspectives of Alzheimer's disease treatments
Davis, J. B., Bountra, C., & Richardson, J. C. (2008) · Handbook of clinical neurology · doi:10.1016/s0072-9752(07)01226-2 · Cited by 2
Usefulness of Cerebrospinal Fluid Biomarkers in Diagnosis of Early Alzheimer's Disease
Herukka, S. (2007) · Cited by 2
Synthesis of Carboranyl Flurbiprofen and Its Biological Evaluation—An Example of Carborane Not as a Phenyl Ring Surrogate
Li, C., Ma, C., Lin, Y., Yuan, C., Hao, G., Zhang, Z., & Wang, S. (2026) · ChemistrySelect · doi:10.1002/slct.202505652 · Cited by 1
Spin-driven enantioselective regulation of cyclooxygenase-2 activity for rheumatoid arthritis therapy via chiral gold nanohelices
Yan, J., Liu, L., Chen, Z., Zhao, Q., Han, X., Wang, Y., Mu, Z., Wang, X., Song, P., Kang, Y., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-71522-9 · Cited by 1
Pharmacology of nivegacetor (RG6289), a potent and selective gamma secretase modulator in clinical development for the treatment of Alzheimer’s disease
Lindemann, L., Lambotte, J., Rothe, J., Messer, J., Diener, C., Pichereau, S., Cantrill, C., Mueggler, T., Honer, M., Beck, J., et al. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1783414 · Cited by 1
Alzheimer's disease
Matthews, B. R., & Miller, B. L. (2009) · Cambridge University Press eBooks · doi:10.1017/cbo9780511581410.005 · Cited by 1
Proceso inflamatorio en la enfermedad de Alzheimer. Papel de las citoquinas
Rubio-Perez, J. M., & Morillas-Ruiz, J. M. (2014) · doi:10.3926/oms.47 · Cited by 2
Reduction of Aβ42 in brains of transgenic APP swe mice by 2‐3‐chlorophenylaminophenylacetate
Cohen, M. P., & Shearman, C. W. (2009) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.2009.05201.x · Cited by 1
The evolution of Alzheimer’s disease therapies: A comprehensive review
Paul, P., Bhattacharjee, A., Bordoloi, S. K., & Paul, U. K. (2024) · Annals of Medical Science and Research · doi:10.4103/amsr.amsr_37_23 · Cited by 1
Therapeutic Strategies in Neurodegenerative Diseases
Eid, A. M., Faridar, A., & Appel, S. H. (2024) · Springer eBooks · doi:10.1007/978-3-031-68237-7_39 · Cited by 1
HPLC/UV analysis of mulberry vinegar and its protective role in LPS-induced cognitive impairment via regulating NF-κB signaling pathway and amyloidogenesis in mice
Bang, S. I., Seo, W. T., Lee, S., Cho, E. J., & Lee, A. Y. (2025) · Food Science and Biotechnology · doi:10.1007/s10068-025-01971-3 · Cited by 1
The Role of Polyphenols in the Treatment of Alzheimer's Disease: Narrative Review
Alattiya, R. H., Tarish, F. K., Hashim, L. L., & Hussain, S. A. (2021) · Al-Rafidain Journal of Medical Sciences · doi:10.54133/ajms.v1i.31 · Cited by 1
Alzheimer’s Disease
Ikezu, T. (2016) · Springer eBooks · doi:10.1007/978-3-319-44022-4_30 · Cited by 1
The Involvement of Aβ in the Neuroinflammatory Response
Eikelenboom, P., van Gool, W. A., Rozemüller, A. J. M., Scheper, W., Veerhuis, R., & Hoozemans, J. J. M. (2006) · Springer eBooks · doi:10.1007/978-1-84628-440-3_4 · Cited by 1
Current and Future Therapies for Alzheimer Disease
Chakrabarty, P., Das, P., & Golde, T. E. (2010) · Wiley eBooks · doi:10.1002/9780470572702.ch34 · Cited by 1
Statistical and Data Mining Methodologies for Behavioral Analysis in Transgenic Mouse Models of Alzheimer’s Disease: Parallels with Human AD Evaluation
Leighty, R. E. (2009) · Digital Commons - University of South Florida (University of South Florida) · Cited by 1
Aging and Cognitive Decline: Neuroprotective Strategies
do Couto, F. S., & de Mendonça, A. (2007) · Springer eBooks · doi:10.1007/978-0-387-70830-0_11 · Cited by 1
Multiple anti‐Alzheimer disease activities of non‐steroidal anti‐inflammatory drugs
Morihara, T., Cole, G. M., TANII, H., Tanaka, T., Kudo, T., & Takeda, M. (2006) · Psychogeriatrics · doi:10.1111/j.1479-8301.2006.00139.x · Cited by 1
Alzheimer’s disease: from pathogenesis to novel therapeutic approaches
Scarpini, E. A., & Galimberti, D. (2009) · Therapy · doi:10.2217/14750708.6.2.259 · Cited by 1
Aspirin and anti-inflammatory drugs for Alzheimer's disease
Davis, R., Isaac, M. G. E. K. N., & Tabet, N. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006378 · Cited by 1
Drug Targets, Target identification, Validation and Screening
Zavitz, K. H., Bartel, P. L., & Hobden, A. N. (2008) · Elsevier eBooks · doi:10.1016/b978-0-12-374194-3.00005-6 · Cited by 1
Regulación de la plasticidad astrocitaria por ibuprofeno y FGF2
Lichtenstein, M. P. (2011) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) · Cited by 1
Current and Prospective Treatments for Alzheimer's Disease (and Other Neurodegenerative Diseases)
Pedrini, S., Morici, M., & Martins, R. N. (2019) · Wiley eBooks · doi:10.1002/9781119356752.ch14 · Cited by 1
NSAIDs and cardiovascular drugs in neurodegenerative and cerebrovascular diseases
Haag, M. D. M. (2009) · RePub (Erasmus University Rotterdam)
Neuroinflammation in Alzheimer's disease: Characterization and modification of the response of transgenic mice to intrahippocampal lipopolysaccharide administration
Herber, D. L. (2004) · Digital Commons - University of South Florida (University of South Florida)
Chapter 1 Amyloid and Amyloid-Like Protein Aggregates in Neurodegenerative Disease
Golde, T. E. (2007) · Blue books of neurology · doi:10.1016/s1877-184x(09)70052-8
γ‐Secretase: An Unusual Enzyme with Many Possible Disease Targets, Including Alzheimer's Disease
Lundkvist, J., & Lendahl, U. (2010) · Methods and principles in medicinal chemistry · doi:10.1002/9783527630943.ch12
GENOME-WIDE ASSOCIATION STUDIES AT THE INTERFACE OF ALZHEIMER'S DISEASE AND EPIDEMIOLOGICALLY RELATED DISORDERS
Simmons, C. R. (2011) · UKnowledge (University of Kentucky)
Gebrauch von non-steroidal antiinflammatory drugs in der Therapie primärer Kopfschmerzerkrankungen
Evers, S., & Summ, O. (2013) · Nervenheilkunde · doi:10.1055/s-0038-1628488
A life span approach to the relationship between cholesterol, late onset Alzheimer's disease, and cognitive functioning among older adults
Downer, B. G. (2014) · UKnowledge (University of Kentucky)
The influence of amyloid-beta, a major pathological marker in Alzheimer's disease, on molecular cognitive processes of APP+PS1 transgenic mice
Dickey, C. A. (2004) · Digital Commons - University of South Florida (University of South Florida)
Diseases: New Concepts of Pathogenesis and Their Therapeutic Implications
Skovronsky, D., Lee, V. M. ‐., & Trojanowski, J. Q. (2006)
Development of the Amyloid Fibril Characterisation Toolbox - New use for old dyes
Lindberg, D. J. (2015) · Chalmers Publication Library (Chalmers University of Technology)
Pharmacological Strategies for Neurodegeneration and Overview of Clinical Trials
Ley, L., & Herdegen, T. (2004) · Springer eBooks · doi:10.1007/1-4020-2541-6_39
Novel regulation of neuronal genes implicated in Alzheimer disease by microRNA
Long, J. M. (2013) · IUScholarWorks (Indiana University) · doi:10.7912/c2/2052
Small Molecule Modulators of Amyloid Formation by Islet Amyloid Polypeptide
Noor, H. (2012) · Academic Commons (Stony Brook University)
Inhibitor and regulator of presenilin for Alzheimer’s disease
Chen, T., Huang, X., Cui, L., & Zhang, Y. (2009) · Shengming kexue
Chronological Primacy of Oxidative-Induced Neuronal Damage in the Pathogenesis of Alzheimer's Disease
Estefan, S. F. (2013) · International Journal of Biochemistry Research & Review · doi:10.9734/ijbcrr/2013/2593
AINEs y estatinas para el tratamiento de la Enfermedad de Alzheimer NSAIs and statins for the treatment of Alzheimer’s disease
Menéndez‐González, M., Rivera, M. M., Pérez‐Piñera, P., & Noguera, M. T. C. (2006) · Dialnet (Universidad de la Rioja)
Therapeutic Targeting of Aβ42
Golde, T. E., Lessard, C. B., & Ran, Y. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802173-6.00005-8
Intraneuronal Amyloid and Inflammation
D’Andrea, M. R. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-804256-4.00007-3
The Current Status of Alzheimer's Disease Treatment
Lanctôt, K. L., Kircanski, I., Chau, S. A., & Herrmann, N. (2012) · Frontiers in neuroscience · doi:10.1201/b11986-5
Nitrate Chimeras: A New Class of Disease Modifying Agents for the Treatment of Alzheimer's Disease
VandeVrede, L. A. (2014) · Figshare

Authors: Eriksen, J. L., Sagi, S. A., Smith, T. E., Weggen, S., Das, P., McLendon, D. C., Ozols, V. V., Jessing, K. W., Zavitz, K. H., Koo, E. H., & Golde, T. E.
Affiliations: Mayo Clinic (US)
University of California San Diego (US)
Corresponding author: Golde, Todd E.
ORCID: Eriksen, Jason L.
Weggen, Sascha
Das, Pritam
Koo, Edward H.
Golde, Todd E.
Venue: Journal of Clinical Investigation
Publisher: American Society for Clinical Investigation
Published: 2003-08-01
Volume: 112
Issue: 3
Pages: 440-449
ISSN: 0021-9738 (ISSN-L)
DOI: 10.1172/jci18162
PMC: PMC166298
OpenAlex: W2103071556
Cited by: 634
References: 52
Citations by year: 2026: 7 · 2025: 12 · 2024: 11 · 2023: 11 · 2022: 15 · 2021: 20 · 2020: 14 · 2019: 15 · 2018: 11 · 2017: 18 · 2016: 25 · 2015: 18 · 2014: 31 · 2013: 32 · 2012: 37
FWCI: 23.24
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Journal of Clinical Investigation (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Funders: Mayo Foundation for Medical Education and Research
National Institutes of Health
National Institute on Aging (P01AG020206, T32AG000216)
National Institute of Neurological Disorders and Stroke (R01NS039072)
Topics: Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Keywords: nonsteroidal anti-inflammatory drugs, gamma-secretase, amyloid-beta 42, Alzheimer's disease, APP transgenic mice, ibuprofen, meclofenamic acid, dapsone, cyclooxygenase inhibition, drug repurposing
MeSH terms: Alzheimer Disease, Animals, Anti-Inflammatory Agents, Non-Steroidal, Brain, Cell Line, Female, Flurbiprofen, Humans, Meclofenamic Acid, Mice, Transgenic, Peptide Fragments, Endopeptidases, Protease Inhibitors, Stereoisomerism, Amyloid beta-Peptides, Aspartic Acid Endopeptidases, Mice, Amyloid Precursor Protein Secretases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

NSAIDs and enantiomers of flurbiprofen target γ-secretase and lower Aβ42 in vivo

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks